A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Mhairi CoplandCono AritiIan F ThomasLaura UptonMia SydenhamPriyanka MehtaShahid IslamLars KjeldsenAlan K BurnettRobert K HillsNigel H RussellMike Dennisnull nullPublished in: British journal of haematology (2023)
Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI-1 trial, we evaluated lenalidomide (LEN) in combination with low-dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone. Two hundred and two patients, randomised 1:1, were evaluable. Overall response rate (CR + CRi) was higher for LDAC + LEN versus LDAC (26% and 13.7% respectively p = 0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC + LEN and LDAC respectively). The addition of LEN was associated with increased toxicity and supportive care requirements.
Keyphrases
- low dose
- newly diagnosed
- clinical trial
- end stage renal disease
- study protocol
- ejection fraction
- high dose
- healthcare
- open label
- peritoneal dialysis
- prognostic factors
- multiple myeloma
- acute myeloid leukemia
- phase iii
- physical activity
- bone marrow
- double blind
- dendritic cells
- oxidative stress
- phase ii
- immune response
- stem cells
- quality improvement
- mesenchymal stem cells
- patient reported outcomes
- metabolic syndrome
- weight loss
- patient reported
- ion batteries
- health insurance